Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: A meta-analysis of randomised controlled trials

International Journal of Clinical Practice

Volumn 67, Issue 9, 2013, Pages 834-842

  Chen, F ^a   Zheng, N ^a   Wang, Y ^a   Wen, J L ^b   Tu, W F ^b   Du, Y Q ^a   Lin, J M ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABSCESS; ADULT; ANTIBIOTIC THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; CONTROLLED STUDY; DIABETIC FOOT; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 84882366613     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12174     Document Type: Article

References (39)

1. Lee SY, Kuti JL, Nicolau DP,. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005; 6: 283-95.
2. Nichols RL,. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44 (Suppl. A): 19-23.
3. DiNubile MJ, Lipsky BA,. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 (Suppl. 2): ii37-50.
4. Fung HB, Chang JY, Kuczynski S,. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63: 1459-80.
5. Lipsky BA, Weigelt JA, Gupta V, et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. J Antimicrob Chemother 2007; 60: 370-6.
6. Raghavan M, Linden PK,. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64: 1621-42.
7. Martin SJ, Zeigler DG,. The use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother 2004; 5: 237-46.
8. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35: 381-9.
9. Lipsky BA, Miller B, Schwartz R, et al. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections. Clin Ther 1999; 21: 675-90.
10. Muller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9.
11. Woodcock KM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6.
12. Aldridge KE, Ashcraft DS,. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-11.
13. Guay DRP,. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag 2006; 2: 417-34.
14. Ashour HM, el-Sharif A,. Microbial spectrum and antibiotic susceptibility profile of Gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol 2007; 25: 576-9.
15. Jacobs E, Dalhoff A, Korfmann G,. Susceptibility patterns of bacterial isolates from hospitalized patients with respiratory tract infections. Int J Antimicrob Agents 2009; 33: 52-7.
16. Giordano P, Song J, Pertel P, et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26: 357-65.
17. Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011; 66: 2632-42.
18. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 2009; 37: 407-17.
19. Moher D, Jadad AR, Tugwell P,. Assessing the quality of randomized controlled trials: current issues and future directions. Int J Technol Assess Health Care 1996; 12: 195-208.
20. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
21. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
22. Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/ clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection 2013; 41: 175-86.
23. http://clinicaltrials.gov/ct2/show/NCT00402727?term= moxifloxacin+AND+skin&rank=2 (accessed March 2013).
24. http://clinicaltrials.gov/ct2/show/NCT00828971?term= moxifloxacin+AND+skin&rank=3 (accessed March 2013).
25. http://clinicaltrials.gov/ct2/show/NCT00997997?term= moxifloxacin+AND+skin&rank=1 (accessed March 2013).
26. Malathum K, Singh KV, Murray BE,. In vitro activity of moxifloxacin, a new 8-methoxyquinolone against Gram-positive bacteria. Diagn Microbiol Infect Dis 1999; 35: 127-33.
27. Jones ME, Visser MR, Klootwijk M, et al. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin resistant and susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999; 43: 421-3.
28. Esposito S, Noviello S, Ianniello F, Novelli A,. In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of Group A beta-haemolytic streptococcus. Chemotherapy 2000; 46: 23-7.
29. Fass RJ,. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997; 41: 1818-24.
30. Ackermann G, Schaumann R, Pless B, et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-32.
31. Poole K,. Mechanisms of bacterial biocide and antibiotic resistance. Symp Ser Soc Appl Microbiol 2002; 31 (Suppl.): 55S-64S.
32. Stass H, Kubitza D,. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl. B): 83-90.
33. Wise R, Andrews JM, Marshall G, Hartman G,. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-10.
34. Ball P, Stahlmann R, Kublin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-50.
35. Stass H, Kubitza D,. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001; 32 (Suppl. 1): 47-50.
36. Song JX, Wassell JT,. Sample size for K 2 × 2 tables in equivalence studies using Cochran's statistic. Control Clin Trials 2003; 24: 378-89.
37. Higgins J, Thompson S, Deeks J, Altman D,. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7: 51-61.
38. Lau J, Ioannidis JPA, Schmid CH,. Summing up the evidence: one answer is not always enough. Lancet 1997; 351: 123-7.
39. Thompson SG,. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351-5.